 |
18 Diseases |  |
8 Trials |
|
8 Trials |  |
244 News |  |
| «12345» |
- | Baraclude (entecavir) / Generic Mfg., Tyzeka (telbivudine) / Novartis
Clinical, Journal: Effects of entecavir, tenofovir and telbivudine treatment on renal functions in chronic hepatitis B patients. (Pubmed Central) - Jul 23, 2019
Telbivudine was superior to the other drugs in terms of renal function. We conclude that an individualized therapy program considering treatment efficacy and side effects is the best option for patients.
- | Tyzeka (telbivudine) / Novartis
Clinical, Journal: A case of telbivudine-related fatal lactic acidosis and multiple organ dysfunction syndrome (Pubmed Central) - Jul 20, 2019
Telbivudine was discontinued, and tenofovir disoproxil fumarate and liver protective drug were used...Such patients are easily misdiagnosed as neuromuscular diseases in the early stage, which might delay the treatment and worsen medical conditions. Clinicians need to be cautious and obtain an early identification to avoid misdiagnosis.
- | tenofovir / ScinoPharm Taiwan
Journal: Effect of antiviral therapy in reducing perinatal transmission of hepatitis B virus and maternal outcomes after discontinuing them. (Pubmed Central) - Jul 19, 2019
Long-term follow-up should be required in such cases. In addition, given that maternal biochemical flare occurred in 18% of mothers, re-administration of antiviral agents might be required.
- | Baraclude (entecavir) / BMS, Tyzeka (telbivudine) / Novartis
Clinical, Journal: Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B. (Pubmed Central) - Jul 3, 2019
In addition, given that maternal biochemical flare occurred in 18% of mothers, re-administration of antiviral agents might be required. Entecavir and tenofovir might be recommended for the treatment of chronic hepatitis B because of having potent antiviral effect, high genetic barriers against resistance and good safety.
- | Vemlidy (tenofovir alafenamide) / Gilead
Clinical, Review, Journal: Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. (Pubmed Central) - Jun 15, 2019
Long-term safety profile of nucleoside analogues is now better defined with more data from large real-life cohorts and clinical trials with long-term follow-up. The new nucleotide analogue, TAF is now available with favourable renal and bone safety profiles.
- | tenofovir / ScinoPharm Taiwan
Retrospective data, Review, Journal: Title: Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: a Systematic Review and Meta-Analysis. (Pubmed Central) - Jun 15, 2019
Thus, included studies were categorized into two main prophylaxis groups: Lamivudine and Entecavir. Results of our meta-analysis suggests that Entecavir is very effective against HBVr, although further clinical trials are required to test efficacy of new antivirals and explore the emerging threat of drug resistance.
- lamivudine / Generic mfg.
Molecular epidemiology and resistance mutations of hepatitis B virus in the last few years (HALL F) - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_4379;
The presence of coinfection with HCV and VHD in our population has been low. Tenofovir maintains sensitivity in 100% of patients with resistance mutations, so it should be considered the treatment of choice.
- | Tyzeka (telbivudine) / Novartis
Enrollment closed, Trial completion date, Trial primary completion date: Tenofovir Versus Tenofovir + Telbivudine for Chronic Hepatitis B (clinicaltrials.gov) - Mar 18, 2019
P4, N=146, Active, not recruiting, Sponsor: Seng Gee Lim
Tenofovir maintains sensitivity in 100% of patients with resistance mutations, so it should be considered the treatment of choice. Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jul 2020 | Trial primary completion date: Jun 2018 --> Jul 2020
- ||||| Tyzeka (telbivudine) / Novartis
Trial completion: Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Jan 31, 2019
P3, N=53, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jul 2020 | Trial primary completion date: Jun 2018 --> Jul 2020 Active, not recruiting --> Completed
- | Tyzeka (telbivudine) / Novartis
New P4 trial: Renoprotective Effects of Telbivudine in Chronic Hepatitis B (clinicaltrials.gov) - Dec 19, 2018
P4, N=31, Completed, Sponsor: The University of Hong Kong
- | Tyzeka (telbivudine) / Novartis
Trial completion date, Trial primary completion date: Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Nov 29, 2018
P3, N=53, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial completion date: Dec 2019 --> Jan 2019 | Trial primary completion date: Dec 2019 --> Jan 2019
- | Tyzeka (telbivudine) / Novartis
Trial completion, Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: The Safety of Anti-viral Therapy in Preventing HBV MTCT in Pregnant Women After Discontinuation (clinicaltrials.gov) - Aug 29, 2018
P4, N=111, Completed, Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
Trial completion date: Dec 2019 --> Jan 2019 | Trial primary completion date: Dec 2019 --> Jan 2019 Not yet recruiting --> Completed | N=200 --> 111 | Trial completion date: Dec 2020 --> Dec 2017 | Initiation date: Apr 2018 --> Jun 2015 | Trial primary completion date: Dec 2020 --> Dec 2017
- | Tyzeka (telbivudine) / Novartis
New P4 trial: The Safety of Anti-viral Therapy in Preventing HBV MTCT in Pregnant Women After Discontinuation (clinicaltrials.gov) - Jul 16, 2018
P4, N=200, Not yet recruiting, Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
- | Tyzeka (telbivudine) / Novartis
Trial completion, Combination therapy: TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction (clinicaltrials.gov) - May 2, 2018
P1/2, N=120, Completed, Sponsor: Fuzhou General Hospital
Not yet recruiting --> Completed | N=200 --> 111 | Trial completion date: Dec 2020 --> Dec 2017 | Initiation date: Apr 2018 --> Jun 2015 | Trial primary completion date: Dec 2020 --> Dec 2017 Active, not recruiting --> Completed
- | Tyzeka (telbivudine) / Novartis
Trial initiation date, Trial primary completion date: STEN: A Two-year Study of Telbivudine in HBeAg Negative Hepatitis (clinicaltrials.gov) - Oct 24, 2017
P4, N=360, Completed, Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
Active, not recruiting --> Completed Initiation date: Sep 2011 --> Jan 2011 | Trial primary completion date: Feb 2013 --> Feb 2014
- |||| Tyzeka (telbivudine) / Novartis
Trial completion: Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B (clinicaltrials.gov) - Jun 15, 2017
P2b, N=130, Completed, Sponsor: Novartis
Initiation date: Sep 2011 --> Jan 2011 | Trial primary completion date: Feb 2013 --> Feb 2014 No longer recruiting --> Completed
- | Tyzeka (telbivudine) / Novartis
Enrollment closed, Combination therapy: TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction (clinicaltrials.gov) - May 16, 2017
P1/2, N=120, Active, not recruiting, Sponsor: Fuzhou General Hospital
No longer recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- ||||| Tyzeka (telbivudine) / Novartis
Enrollment closed, Enrollment change: Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Feb 16, 2017
P3, N=53, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting | N=150 --> 53
- Tyzeka (telbivudine) / Novartis
Trial primary completion date, Post-transplantation: Replacement of Lamivudine by Telbivudine to Improve Renal Function (clinicaltrials.gov) - Feb 7, 2017
P2/3, N=120, Completed, Sponsor: Chang Gung Memorial Hospital
Recruiting --> Active, not recruiting | N=150 --> 53 Trial primary completion date: Dec 2015 --> Dec 2016
- Tyzeka (telbivudine) / Novartis
Enrollment change, Trial withdrawal, Trial primary completion date: Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks (clinicaltrials.gov) - Sep 23, 2016
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Dec 2016 N=90 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Dec 2011 --> Apr 2011
- |||| Tyzeka (telbivudine) / Novartis
Trial primary completion date: Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Aug 9, 2016
P3, N=150, Recruiting, Sponsor: Novartis Pharmaceuticals
N=90 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Dec 2011 --> Apr 2011 Trial primary completion date: May 2018 --> Dec 2019
- Tyzeka (telbivudine) / Novartis
Enrollment open, Enrollment change, Combination therapy: TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction (clinicaltrials.gov) - Aug 2, 2016
P1/2, N=120, Enrolling by invitation, Sponsor: Fuzhou General Hospital
Trial primary completion date: May 2018 --> Dec 2019 Active, not recruiting --> Enrolling by invitation | N=90 --> 120
- Tyzeka (telbivudine) / Novartis
Enrollment change, Trial withdrawal, Trial primary completion date: Effect of Telbivudine on Renal Function and Proteinuria in Patients With CHB & Chronic Renal Diseases (clinicaltrials.gov) - Jul 29, 2016
P=N/A, N=0, Withdrawn, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Enrolling by invitation | N=90 --> 120 N=20 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2019 --> Jun 2015
- ||||| Tyzeka (telbivudine) / Novartis
New P4 trial: EFFORT Further Extension Study (clinicaltrials.gov) - Jul 7, 2016
P4, N=130, Active, not recruiting, Sponsor: Nanfang Hospital of Southern Medical University
- | Tyzeka (telbivudine) / Novartis
New P4 trial: Tenofovir Versus Tenofovir + Telbivudine for Chronic Hepatitis B (clinicaltrials.gov) - May 18, 2016
P4, N=146, Recruiting, Sponsor: Seng Gee Lim
- | Tyzeka (telbivudine) / Novartis
Trial completion, Post-transplantation: Replacement of Lamivudine by Telbivudine to Improve Renal Function (clinicaltrials.gov) - Apr 8, 2016
P2/3, N=120, Completed, Sponsor: Chang Gung Memorial Hospital
N=20 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2019 --> Jun 2015 Enrolling by invitation --> Completed
- |||| Tyzeka (telbivudine) / Novartis
Trial completion: Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept (clinicaltrials.gov) - Mar 25, 2016
P4, N=241, Completed, Sponsor: Novartis Pharmaceuticals
Enrolling by invitation --> Completed Recruiting --> Completed
- Tyzeka (telbivudine) / Novartis
Trial completion, Trial primary completion date: To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B (clinicaltrials.gov) - Mar 24, 2016
P=N/A, N=69, Completed, Sponsor: Institute of Liver and Biliary Sciences, India
Recruiting --> Completed Withdrawn --> Completed | Trial primary completion date: Apr 2015 --> Apr 2014
- Tyzeka (telbivudine) / Novartis
Trial completion, Enrollment change, Trial primary completion date: Study of Telbivudine in Chronic Hepatitis B (clinicaltrials.gov) - Feb 29, 2016
P=N/A, N=160, Completed, Sponsor: Chang Gung Memorial Hospital
Withdrawn --> Completed | Trial primary completion date: Apr 2015 --> Apr 2014 Recruiting --> Completed | N=200 --> 160 | Trial primary completion date: Jan 2012 --> Jan 2016
- | Pegasys (pegylated interferon α -2a) / Roche, Tyzeka (telbivudine) / Novartis
New P1/2 trial: CTHBVACADCHB: A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB (clinicaltrials.gov) - Nov 27, 2015
P1/2, N=450, Not yet recruiting, Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
- | Tyzeka (telbivudine) / Novartis
Trial completion, Enrollment change: TERESA: Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B (clinicaltrials.gov) - Jun 25, 2015
P3, N=98, Completed, Sponsor: Asan Medical Center
Recruiting --> Completed | N=200 --> 160 | Trial primary completion date: Jan 2012 --> Jan 2016 Recruiting --> Completed | N=184 --> 98
- Tyzeka (telbivudine) / Novartis
Enrollment change, Trial withdrawal, Trial primary completion date, Monotherapy: Randomized Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug in HBeAg Negative Chronic Hepatitis B Patients (clinicaltrials.gov) - Jun 16, 2015
P=N/A, N=0, Withdrawn, Sponsor: Institute of Liver and Biliary Sciences, India
Recruiting --> Completed | N=184 --> 98 N=90 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2013 --> Jun 2011
- Tyzeka (telbivudine) / Novartis
Enrollment change, Trial withdrawal: To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=0, Withdrawn, Sponsor: Institute of Liver and Biliary Sciences, India
N=90 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2013 --> Jun 2011 N=80 --> 0 | Suspended --> Withdrawn
- || Tyzeka (telbivudine) / Novartis
New P2/3 trial, Post-transplantation: Replacement of Lamivudine by Telbivudine to Improve Renal Function (clinicaltrials.gov) - May 19, 2015
P2/3, N=120, Enrolling by invitation, Sponsor: Chang Gung Memorial Hospital
- Tyzeka (telbivudine) / Novartis
Trial completion: Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B (clinicaltrials.gov) - May 10, 2015
P3, N=0, Completed, Sponsor: Novartis
N=80 --> 0 | Suspended --> Withdrawn No longer recruiting --> Completed
- Tyzeka (telbivudine) / Novartis
Trial completion: An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B (clinicaltrials.gov) - May 10, 2015
P2b, N=0, Completed, Sponsor: Novartis
No longer recruiting --> Completed No longer recruiting --> Completed
- Tyzeka (telbivudine) / Novartis
Trial completion: Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B (clinicaltrials.gov) - May 10, 2015
P3, N=0, Completed, Sponsor: Novartis
No longer recruiting --> Completed No longer recruiting --> Completed
- Tyzeka (telbivudine) / Novartis
Trial suspension: To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=80, Suspended, Sponsor: Institute of Liver and Biliary Sciences, India
No longer recruiting --> Completed Recruiting --> Suspended
- Tyzeka (telbivudine) / Novartis
Trial completion: A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B (clinicaltrials.gov) - Mar 18, 2015
P3, N=0, Completed, Sponsor: Novartis
Recruiting --> Suspended No longer recruiting --> Completed
- Tyzeka (telbivudine) / Novartis
Enrollment open, Trial initiation date, Trial primary completion date: Effect of Telbivudine on Renal Function and Proteinuria in Patients With CHB & Chronic Renal Diseases (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=20, Recruiting, Sponsor: Chinese University of Hong Kong
No longer recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jun 2013 --> Dec 2013 | Trial primary completion date: Dec 2018 --> Jun 2019
- |||||| Tyzeka (telbivudine) / Novartis
Enrollment open: Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Jan 20, 2015
P3, N=150, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Jun 2013 --> Dec 2013 | Trial primary completion date: Dec 2018 --> Jun 2019 Not yet recruiting --> Recruiting
- | Tyzeka (telbivudine) / Novartis
New P1/2 trial, Combination therapy: TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction (clinicaltrials.gov) - Jan 15, 2015
P1/2, N=90, Active, not recruiting, Sponsor: Fuzhou General Hospital
- Tyzeka (telbivudine) / Novartis
Trial completion, Enrollment change: Telbivudine Therapy in HBeAg-positive Pregnant Women to Prevent Mother-to-infant Transmission of HBV (clinicaltrials.gov) - Dec 5, 2014
P4, N=335, Completed, Sponsor: Yi-Hua Zhou
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=240 --> 335
- Clinical: The Effect of Anti-viral Drugs Used in Late Pregnancy on Long-term Development of Children (clinicaltrials.gov) - Nov 28, 2014
P=N/A, N=400, Enrolling by invitation, Sponsor: Beijing Ditan Hospital
- Tyzeka (telbivudine) / Novartis
Clinical: Efficacy of Antiviral Therapy in Pregnancy in Preventing Vertical Transmission of HBV in Mothers With a High Viral Load (clinicaltrials.gov) - Oct 2, 2014
P=N/A, N=600, Enrolling by invitation, Sponsor: Beijing Ditan Hospital
- Tyzeka (telbivudine) / Novartis
Enrollment closed, Trial primary completion date: Telbivudine Therapy in HBeAg-positive Pregnant Women to Prevent Mother-to-infant Transmission of HBV (clinicaltrials.gov) - Sep 28, 2014
P4, N=240, Active, not recruiting, Sponsor: Yi-Hua Zhou
Active, not recruiting --> Completed | N=240 --> 335 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Oct 2014
- ||| Tyzeka (telbivudine) / Novartis
Enrollment closed: EFFORT-Ex: EFFORT Extension Study (clinicaltrials.gov) - Jun 19, 2014
P4, N=576, Active, not recruiting, Sponsor: Nanfang Hospital of Southern Medical University
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Oct 2014 Recruiting --> Active, not recruiting
- Tyzeka (telbivudine) / Novartis
Trial primary completion date: To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B (clinicaltrials.gov) - May 6, 2014
P=N/A, N=80, Recruiting, Sponsor: Institute of Liver and Biliary Sciences, India
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2013 --> Apr 2015
- Tyzeka (telbivudine) / Novartis
Trial completion date: To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B (clinicaltrials.gov) - May 6, 2014
P=N/A, N=80, Recruiting, Sponsor: Institute of Liver and Biliary Sciences, India
Trial primary completion date: Nov 2013 --> Apr 2015 Trial completion date: Jun 2014 --> Apr 2015
- |||| Tyzeka (telbivudine) / Novartis
Clinical: A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB) (clinicaltrials.gov) - Mar 5, 2014
P4, N=105, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jun 2014 --> Apr 2015 Active, not recruiting --> Completed